about
Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 BindingSevere fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complexCDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery.Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 2-model applications.A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 1-theoretical model.The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models.Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.Mannan binding lectin and viral hepatitis.A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics.A review of quantitative modeling of B cell responses to antigenic challenge.Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products.Preclinical studies of PF-04849285, an interferon-α8 fusion protein for the treatment of HCV.Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets.Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry.Recombinant human L-ficolin directly neutralizes hepatitis C virus entry.Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease.A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo.Induction of TNF-alpha release from human buffy coat cells by Pseudomonas aeruginosa is reduced by lung surfactant protein AA Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins
P50
Q27477468-44FB4CCD-F31D-4C4F-A107-A41211D66F29Q27478140-F187AD10-BE61-43BB-9EDB-C6DF0BC603B0Q31135534-5FF6ABE2-60F5-409E-A096-6F5C834D7C22Q33234572-21F0CF52-638D-4C0D-AE43-DCF1AC4DE91BQ34413009-02109A6E-B8B0-4E7C-A76E-0176E0189201Q34413016-B8558442-02C1-4B0F-8CFE-CF63B3F4BCBCQ35001424-9F94631F-0954-49DB-89FE-DDDFC13A4058Q35856534-996129E1-7FCC-458E-9C0E-DC95D9C73014Q36678442-63E80C37-7C79-4E61-895A-E48ED3E63149Q37207825-3BD2883F-96AD-41FC-8550-B0FCBCF7B0B0Q38261215-30E6ADFC-F7A3-48D1-B985-AD5279751D75Q38423693-AC5E931E-B09C-4DBA-93FE-56D79B2AE9EEQ39364353-2754B59B-032A-49B8-9529-5FE814859605Q40162274-DBABF3A0-227B-4E59-8D29-CC8A0C23727BQ40385442-F7503268-2925-4F05-9E71-2ED3EC708D5AQ42024261-F03E62BB-A4C2-4F88-8C50-757B886F09DFQ42217086-F72104AF-4E38-4222-8FD8-6AC9AD2D0824Q43047439-B0D1879E-5897-4E43-922F-D70074F66D99Q45746389-4BE5179B-D809-419C-B627-319D70967164Q77518993-19D72739-4827-41CA-B5F5-0394EEC61348Q90142674-0FD7416C-50CF-4476-8DDB-521CD03E1A3D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Timothy P Hickling
@es
Timothy P. Hickling
@en
Timothy P. Hickling
@nl
Timothy P. Hickling
@sl
type
label
Timothy P Hickling
@es
Timothy P. Hickling
@en
Timothy P. Hickling
@nl
Timothy P. Hickling
@sl
prefLabel
Timothy P Hickling
@es
Timothy P. Hickling
@en
Timothy P. Hickling
@nl
Timothy P. Hickling
@sl
P106
P1153
6603147046
P21
P31
P496
0000-0002-8918-2140
P569
2000-01-01T00:00:00Z